Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04560816 · ClinicalTrials.gov registry record · Phase 1
A Study of the Cardiac Effects of ALXN1840 in Healthy Adults
A Phase 1 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT04560816 is a Phase 1 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 57 participants.
The verdict
NCT04560816, a Phase 1 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
This study will evaluate the effect of a supratherapeutic dose of ALXN1840 on the heart rate (HR)-corrected QT interval (QTc) in healthy adult participants. Moxifloxacin will be used as the active control.
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG ALXN1840
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2020-07-24 |
| Est. Completion | 2021-03-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04560816
The ClinicalTrials.gov registry entry for NCT04560816 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04560816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04560816 about?
NCT04560816 is a clinical study titled "A Study of the Cardiac Effects of ALXN1840 in Healthy Adults". This study will evaluate the effect of a supratherapeutic dose of ALXN1840 on the heart rate (HR)-corrected QT interval (QTc) in healthy adult participants. Moxifloxacin will be used as the active control.
What is the current status of trial NCT04560816?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2020-07-24. Estimated completion is 2021-03-24.
What interventions are being tested in trial NCT04560816?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), ALXN1840 (DRUG).
Who is sponsoring clinical trial NCT04560816?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.